Recurrent Epithelial Ovarian Cancer
8 clinical trials · Condition
◉ Watch Recurrent Epithelial Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (NCT05335993) | CanariaBio Inc. | 2022-07-25 |
| Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer (NCT02785250) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2016-04-01 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01853644) | Northwestern University | 2013-06-06 |
| Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer (NCT01815528) | JSehouli | 2013-03-01 |
| Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (NCT01472783) | Vejle Hospital | 2011-11-01 |
| Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients (NCT01334047) | Steinar Aamdal | 2011-04-01 |
Track Recurrent Epithelial Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.